Sinking Burning Rock faces de-listing. But could privatization bid come first?
The cancer-screening products maker is in danger of being forcibly delisted due to its sinking stock price, as income from its former top revenue source tumbles amid an industry crackdown…
Estrella Immunopharma nears completion of SPAC listing
The developer of T-cell cancer therapies is based in California, but says it ‘may be subject to risks’ due to its numerous China connections Key Takeaways: Estrella Immunopharma is nearing…
New Horizon Health finds formula for profits ahead of schedule
One of China’s leading makers of early cancer screening products recorded an adjusted profit in the first half of the year as its revenue more than tripled Key Takeaways: New…
Heated market for dueling blood cancer drugs lands BeiGene in court
The Chinese drug maker was sued by U.S. rival AbbVie over alleged patent infringement involving a key product for both companies Key Takeaways: A unit of AbbVie has sued BeiGene…
Lepu Biopharma Marches Towards First Sales as Costs Mount
Company’s Puyouheng cancer immunotherapy drug was approved for two indications in China, becoming its first commercialized product Key Takeaways: Lepu Biopharma will incur more operational costs as it builds up…
Burning Rock Localizes as Investors Grow Impatient
Cancer testing company reported a widening loss in the first quarter as it spent heavily to build up its localized business model of providing services through partner hospitals Key Takeaways:…
I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat
Cancer drug maker has been in a wide range of market-moving headlines lately, though its stock still trades near an all-time low Key Takeaways: I-Mab was placed on a list…